Summary & Overview
HCPCS J7209: Injection, Factor VIII (Nuwiq), Recombinant, 1 IU
HCPCS Level II code J7209 represents an injectable recombinant factor VIII product (Nuwiq) billed per 1 international unit. This code is used to document administration or provision of a biologic replacement therapy for patients with hemophilia A and is relevant across inpatient outpatient infusion and ambulatory care settings. Nationally, accurate use of J7209 affects medical billing, drug utilization tracking, and coverage determinations for high-cost specialty therapies.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and common sites of service, typical payer coverage considerations, and billing elements associated with a unit-based biologic drug code. The publication also summarizes common modifiers seen in practice, although specific modifier application varies by payer policy.
This summary provides benchmarks for typical billing practice, highlights payer policy themes relevant to high-cost injectable biologics, and outlines where policy updates or coding clarifications may affect claims processing. Data not available in the input is noted where applicable, and the content focuses on national policy and clinical context rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J7209 describes an injection of factor VIII (antihemophilic factor, recombinant), marketed as Nuwiq, billed per 1 international unit (1 i.u.). This entry represents a biologic replacement therapy used to treat hemophilia A by providing recombinant factor VIII to support clotting.
-
Service type: Injectable biologic therapy
-
Typical site of service: Hospital outpatient departments, infusion centers, physician offices, and other ambulatory care settings where intravenous factor replacement is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual with hemophilia A presenting for routine prophylactic or on-demand replacement therapy with recombinant factor VIII (Nuwiq). The clinical workflow begins with assessment by a hematologist or infusion clinic nurse who verifies the patient’s weight, current factor VIII trough/peak levels if available, recent bleeding history, and prescription for J7209 dosed in international units (I.U.). The medication is prepared in a clinic pharmacy or infusion suite, with dose calculated from ordered I.U. and reconstituted per manufacturer instructions. The patient is positioned for intravenous access, either via peripheral IV or established central venous access. Nursing documents lot number, expiration, and vial usage; administers J7209 intravenously over the recommended infusion rate while monitoring for infusion reactions. Post-infusion, the patient is observed for a brief period for signs of hypersensitivity or thrombosis, vital signs are recorded, and administration details are supplied to the hematologist and the patient’s payer. Typical sites of service include an outpatient infusion center, hospital outpatient department, emergency department for bleeding episodes, or home infusion programs supervised by credentialed infusion nurses. Common clinical scenarios include perioperative factor coverage, treatment of acute hemarthrosis, and routine prophylaxis in severe hemophilia A.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|